在rhabdomyosarcoma中对蛋白质平衡网络的活体操纵
Kristen Kwong1, Yue Pan1, Jacqueline Morales1
1Department of Pediatrics, Division of Oncology, University of California San Francisco, San Francisco, CA 94143, USA.
Oncotarget
|August 29, 2025
概括
用p97抑制剂向蛋白质稳态 (蛋白质稳态) 是对肌肉瘤 (RMS) 治疗有前途的. 这种方法激活了未折叠的蛋白质反应 (UPR) 并诱导癌细胞死亡,提供了一个新的治疗策略.
科学领域:
- 分子生物学
- 癌症生物学
- 药物发现
背景情况:
- 蛋白质平衡 (蛋白质平衡) 网络对于细胞健康至关重要,并且在癌症中经常受到调节.
- 儿科软组织肉瘤 (RMS) 对复发患者的治疗选择有限.
- 使用MAL3-101抑制热冲击蛋白70-kD (HSP70) 伴侣,通过未折叠蛋白反应 (UPR) 激活诱导RMS细胞死亡.
研究的目的:
- 研究蛋白质稳定抑制剂作为RMS的治疗策略.
- 为了选可能模仿MAL3-101体内效应的蛋白质稳定成分.
- 在RMS中探索向VCP (p97 ATPase) 的治疗潜力.
主要方法:
- 查蛋白质稳定组件
- 在RMS细胞中抑制VCP (p97 ATPase) 和评估UPR激活和亡.
- 在小鼠模型和患者衍生异体移植中评估临床前的p97抑制剂.
- 对抗性瘤进行RNA测序以识别生物标志物.
主要成果:
- 与MAL3-101类似的VCP抑制激活了UPR并诱导了RMS亡.
- 与MAL3-101相比,临床前的p97抑制剂表现出改善的生物可用性和抗瘤活性.
- 瘤异位移植对p97抑制剂的敏感性有所变化,耐药性与自性增加有关.
结论:
- 蛋白质稳定抑制,特别是针对VCP,是减缓RMS生长的可行治疗策略.
- 抗性瘤中自的增加表明它是蛋白质稳定性适应性的生物标志物.
- 针对蛋白质稳定网络中的补偿机制可能导致RMS的协同治疗结果.
相关概念视频
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K


